{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:05:03Z","timestamp":1787598303364,"version":"build-2736575974"},"reference-count":119,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.4155\/fmc.14.24","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T17:01:38Z","timestamp":1401901298000},"page":"675-695","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Bruton's TK Inhibitors: Structural Insights and Evolution of Clinical Candidates"],"prefix":"10.1080","volume":"6","author":[{"given":"Li","family":"Xing","sequence":"first","affiliation":[{"name":"Biotherapeutics Chemistry, Pfizer Inc, 200 Cambridgepark Drive, Cambridge, MA02140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Wellesley College, 106 Central Street, Wellesley, MA02481, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00225.x"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2010.517750"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1838"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/28962"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203958"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00748.x"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00741.x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.051626198"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-003921"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115606"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8332901"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8332900"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.134.5.3070"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.03978.x"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s12160295"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.2.205"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.502"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.481"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.06.168"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3400"},{"key":"e_1_3_2_29_1","unstructured":"Pharmacyclics Inc.: full prescribing information for IMBRUVICA\u2122. www.imbruvica.com\/downloads\/Prescribing_Information.pdf"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3656"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203489"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-090308-173656"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.3.6.595"},{"issue":"15","key":"e_1_3_2_37_1","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar B","year":"2002","unstructured":"Nagar B , BornmannWG, PellicenaPet al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res.62 (15), 4236\u20134243 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00215-6"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1168"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104828200"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.321"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.575"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81066-1"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80356-1"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80357-3"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2010.00993.x"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300035p"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.10.028"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M807850200"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2011.01230.x"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9002928"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.03.012"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050736c"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000500"},{"key":"e_1_3_2_56_1","unstructured":"Rigel Pharmaceuticals Inc.: fostamatinib update following end-of-Phase II meeting with US FDA. www.rigel.com\/rigel\/ITP"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032151"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543770903059281"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2009.00785.x"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220843110"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00656-5"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsb770"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2005.04.011"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2010.520700"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.03.016"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101499u"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400031200"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.14.9587"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2004.045"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2006.10.050"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152007784111331"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101396q"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1126\/science1108367"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.8707"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.181545"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040840"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.187740"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"issue":"10","key":"e_1_3_2_79_1","first-page":"286","article-title":"PCI-45292, a novel Btk Inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis","volume":"62","author":"Chang BY","year":"2010","unstructured":"Chang BY , ThiemannP, FrancescoMet al. PCI-45292, a novel Btk Inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis. Arthritis Rheum.62 (Suppl. 10), 286 (2010).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8012"},{"key":"e_1_3_2_82_1","unstructured":"Pollyea DA SmithS FowlerN. A Phase I dose escalation study of the BTK inhibitor PCI-32765 in relapsed and refractory B cell non-hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay. Presented at: 51st ASH Annual Meeting and Exposition. LA USA 5\u20138 December 2010."},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203489"},{"key":"e_1_3_2_85_1","doi-asserted-by":"crossref","unstructured":"Brown J HarbW SharmanJ. Phase 1 study of single agent CC-292 a highly selective Bruton's tyrosine kinase (BTK) inhibitor in relapsed\/refractory chronic lymphocytic leukemia (CLL) and B-cell non-hodgkin lymphoma (BNHL). Presented at: 18th Annual Congress of the European Hematology Association. Stockholm Sweden 13\u201316 June 2013.","DOI":"10.1182\/blood.V122.21.1630.1630"},{"issue":"10","key":"e_1_3_2_86_1","article-title":"Development of Bruton's tyrosine kinase (BTK) inhibitor, ONO-4059: efficacy in a collagen induced arthritis (CIA) model indicates potential treatment for rheumatoid arthritis (RA)","volume":"64","author":"Yoshizawa T","year":"2012","unstructured":"Yoshizawa T , ArizaY, UedaY, HottaS, NaritaM, KawabataK. Development of Bruton's tyrosine kinase (BTK) inhibitor, ONO-4059: efficacy in a collagen induced arthritis (CIA) model indicates potential treatment for rheumatoid arthritis (RA). Arthritis Rheum.64 (Suppl. 10), 1660 (2012).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_87_1","unstructured":"CGI Pharmaceuticals Inc.: WO2005005429 (2005)."},{"key":"e_1_3_2_88_1","unstructured":"CGI Pharmaceuticals Inc.: WO2005014599 (2005)."},{"key":"e_1_3_2_89_1","unstructured":"CGI Pharmaceuticals Inc.: WO2005047290 (2005)."},{"key":"e_1_3_2_90_1","unstructured":"Gilead Connecticut Inc.; Genentech Inc.: WO2012030990 (2012)."},{"key":"e_1_3_2_91_1","unstructured":"Gilead Connecticut Inc.; Genentech Inc.: WO2012031004 (2012)."},{"key":"e_1_3_2_92_1","unstructured":"Genentech Inc.: WO2013067260 (2013)."},{"key":"e_1_3_2_93_1","unstructured":"Genentech Inc.: WO2013067274 (2013)."},{"key":"e_1_3_2_94_1","unstructured":"Genentech Inc.: WO2013067277 (2013)."},{"key":"e_1_3_2_95_1","unstructured":"Roche Palo Alto LLC: US20090105209 (2009)."},{"key":"e_1_3_2_96_1","unstructured":"Roche Palo Alto LLC: WO2009077334 (2009)."},{"key":"e_1_3_2_97_1","unstructured":"Roche Palo Alto LLC: US20090306041 (2009)."},{"key":"e_1_3_2_98_1","unstructured":"Roche Palo Alto LLC: WO2010006947 (2010)."},{"key":"e_1_3_2_99_1","unstructured":"Roche Palo Alto LLC: WO2010122038 (2010)."},{"key":"e_1_3_2_100_1","unstructured":"F. Hoffmann-La Roche Ag.: US20100222325 (2010)."},{"key":"e_1_3_2_101_1","unstructured":"Roche Palo Alto LLC: WO2010000633 (2010)."},{"key":"e_1_3_2_102_1","unstructured":"F. Hoffmann-La Roche Ag.: WO2012020008 (2012)."},{"key":"e_1_3_2_103_1","unstructured":"F. Hoffmann-La Roche Ag.: WO2012156334 (2012)."},{"key":"e_1_3_2_104_1","unstructured":"F. Hoffmann-La Roche Ag.: WO2013083666 (2013)."},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_3_2_106_1","unstructured":"Bristol-Myers Squibb Company: WO2008116064 (2008)."},{"key":"e_1_3_2_107_1","unstructured":"Bristol-Myers Squibb Company: WO2010011837 (2010)."},{"key":"e_1_3_2_108_1","unstructured":"Bristol-Myers Squibb Company: WO2010160303 (2010)."},{"key":"e_1_3_2_109_1","unstructured":"Bristol-Myers Squibb Company: WO2011159857 (2011)."},{"key":"e_1_3_2_110_1","unstructured":"Bristol-Myers Squibb Company: WO2011019780 (2011)."},{"key":"e_1_3_2_111_1","unstructured":"Biogen Idec Ma Inc.; Sunesis Pharmaceuticals Inc.: WO2011029043 (2011)."},{"key":"e_1_3_2_112_1","unstructured":"Biogen Idec Ma Inc.; Sunesis Pharmaceuticals Inc.: WO2011029046 (2011)."},{"key":"e_1_3_2_113_1","unstructured":"Merck Sharp & Dohme Corp.: WO2013010380 (2013)."},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_2_115_1","unstructured":"Pharmacyclics Inc.: news release. http:\/\/ir.pharmacyclics.com\/releasedetail.cfm?ReleaseID=807003"},{"key":"e_1_3_2_116_1","unstructured":"Pharmacyclics Inc.: US20100254905 (2010)."},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.09.008"},{"key":"e_1_3_2_118_1","unstructured":"Locus Pharmaceuticals Inc.: WO2010126960 (2010)."},{"key":"e_1_3_2_119_1","unstructured":"University of Utah Research Foundation: WO2012135801 (2012)."},{"key":"e_1_3_2_120_1","unstructured":"ClinicalTrials.gov: NCT01659255\n          . www.clinicaltrials.gov\/show\/NCT01659255"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3410"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8008597"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.14.24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:49:04Z","timestamp":1716493744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.14.24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.4155\/fmc.14.24"],"URL":"https:\/\/doi.org\/10.4155\/fmc.14.24","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-06-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}